Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Other Non-current Assets

Long-term assets not reported separately.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Other Non-current Assets · Q2 FY2026 · quarter ended Jun 2026

Other non-current assets rises 13.9% from a year ago

Other non-current assets stood at $10.46M at the end of Q2 FY2026, up 13.9% from a year earlier and down 9.3% from the prior quarter. Over 3 fiscal years it compounded at +331.4% a year.

Context

  • Other non-current assets amounted to 0.9% of total assets at the end of Q2 FY2026, down 2.0 pp from a year earlier.
  • Other non-current assets increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current assets keeps rising in the next quarterly balance sheet after a +13.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.46M-9.3% QoQ
Last fiscal yearDec 2025
$9.72M+0.9% YoY
Year agoJun 2025
$9.18M+13.9% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.9%——
1 year+0.9%——
3-year CAGR+331.4%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
9.72M USD
Year-over-year change
+0.9%

Other Non-current Assets vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's Jun 2026 other non-current assets of $10.46M is the highest of the 10 companies compared; the peer median is $919K.
  • Its year-over-year change of +13.9% is the 3rd highest of 10, against a peer median of -14.9%.
  • Other non-current assets amounts to 0.9% of total assets for DNTH, versus a peer median of 0.7%.
DNTH Competitors Peer median
Other Non-current Assets for DNTH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DNTHDianthus Therapeutics, Inc.Jun 2026$10.46M +13.9%+331.4%0.9%
RNACCartesian Therapeutics, Inc.Mar 2026$5.55M -28.1%+320.6%1.9%
VERAVera Therapeutics, Inc.Jun 2026$3.8M +7.1%+105.1%0.7%
ALMSAlumis Inc. Common StockJun 2026$3.28M -14.9%+88.2%0.6%
MLTXMoonLake ImmunotherapeuticsMar 2026$1.34M -20.8%—0.3%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$919K +93.9%+21.1%0.9%
IMVTImmunovant, Inc.Sep 2026$659K -92.5%—0.1%
QTTBQ32 Bio Inc.Mar 2026$647K -40.7%—1.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$646K +1857.6%+36.9%1.2%
ANABAnaptysBio, Inc.Mar 2026$256K +0.0%+0.0%0.1%
Peer median (excluding DNTH) $919K-14.9%+62.5%0.7%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents131.65M15.37M132.33M22.79M51.09M
Short-term Investments45.28M60.13M41.39M252.45M353.21M
Net Receivables05.64M478K807K102K
Inventory00000
Other Current Assets3.77M53K504K355K5.04M
Total Current Assets180.69M82.03M177.45M280.9M409.44M
Property, Plant & Equipment (Net)7.46M956K800K1.75M1.63M
Goodwill00000
Intangible Assets00000
Long-term Investments1.78M0081.73M110.14M
Tax Assets00000
Other Non-current Assets0121K1.15M9.63M9.72M
Total Non-current Assets9.24M1.08M1.95M93.1M121.48M
Total Assets189.93M83.11M179.41M374.01M530.92M
Account Payables3.04M1.17M2.61M4.58M9.73M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0100K100K479K1.19M
Other Current Liabilities4.48M2.08M5.36M5.15M9.52M
Total Current Liabilities10.86M8.23M9.63M18.45M30.73M
Long-term Debt00001.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0791K736K1.91M5.77M
Other Non-current Liabilities6.4M0000
Total Non-current Liabilities6.4M1.23M904K3.08M6.79M
Total Liabilities17.26M9.45M10.54M21.53M37.52M
Common Stock59K015K31K43K
Retained Earnings(325.57M)(45.87M)(89.42M)(174.39M)(336.73M)
Accumulated OCI(30K)(161K)47K106K489K
Other Stockholders Equity00000
Minority Interest00000
Total Equity172.67M73.66M168.87M352.48M493.4M
Total Debt0788K585K1.49M1.39M
Net Debt(131.65M)(14.58M)(131.74M)(21.3M)(49.7M)

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.